Stocks Health care PPCB
NASDAQ · Health carePropanc Biopharma, Inc. (PPCB)
It posted a net loss of $18.9M. In fiscal 2026 capital spending exceeded operating cash flow by $5.7M. At June 30, 2026 it held $832K in cash. Its latest periodic report to the SEC is the annual report (10-K) filed on September 25, 2026.
Key facts about Propanc Biopharma, Inc.
- Net worth
- Propanc Biopharma, Inc. has a market value (market cap) of $6.4M at the latest share price, and shareholders' equity of $9.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2026 operations used $5.7M of cash.
- Latest report
- The latest periodic report (annual report, 10-K) was filed with the SEC on September 25, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Propanc Biopharma, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Propanc Biopharma, Inc. does
Propanc Biopharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PPCB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | n/a | -$18.9M | -$17.62 | -$5.7M |
| 2025 | n/a | -$58.9M | -$371.22 | n/a |
| 2024 | n/a | -$1.8M | -$35,510.38 | n/a |
| 2023 | n/a | -$2.7M | -$3,195,934.22 | n/a |
| 2022 | n/a | -$2.7M | -$87,408,800.97 | n/a |
| 2021 | n/a | -$2M | -$1,420,415.21 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Propanc Biopharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 5, 2026IPO registration S-1
- September 25, 2026Annual report10-K · period to June 30, 2026Propanc Biopharma reported no revenue and a net loss of $18,862,710 for fiscal year 2026 amid ongoing going concern warnings.Diluted EPS -$17.62 versus -$371.22.
- August 21, 2026Form DEF 14C filing DEF 14C
- August 5, 2026Form PRE 14C filing PRE 14C
- July 17, 2026IPO registration S-1
- July 14, 2026
- May 14, 2026
- April 10, 2026IPO registration S-1
- March 31, 2026Form DEF 14C filing DEF 14C
- March 20, 2026Form PRE 14C filing PRE 14C
Insider trades
What the people running Propanc Biopharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Questions about PPCB
What does Propanc Biopharma, Inc. do?
Propanc Biopharma, Inc. is a company in the Health care sector, listed on NASDAQ as PPCB. Its shares trade on NASDAQ under the ticker PPCB.
What is Propanc Biopharma, Inc.'s net worth?
Propanc Biopharma, Inc. has a market value (market cap) of $6.4M at the latest share price, and shareholders' equity of $9.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Propanc Biopharma, Inc. profitable?
No. In fiscal 2026 it reported a net loss of $18.9M.
When did Propanc Biopharma, Inc. last report?
Its most recent periodic report is the annual report (10-K) filed on September 25, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the iPO registration from October 5, 2026.
When is Propanc Biopharma, Inc.'s next earnings report?
Propanc Biopharma, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare PPCB with
Follow PPCB
Get an email when Propanc Biopharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Propanc Biopharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.